Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons in the Treatment of Obesity
Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons (Heliosphere Bag®) in the Treatment of Obesity: A Prospective Clinical Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Intragastric balloon (IGB) implantation is a widely used technique to treat overweight subjects and those with mild obesity. The effectiveness of the air filled balloon (Heliosphere BAG®) in improving weight loss, reduction of BMI, percentage of body weight loss, percentage of excess weight loss and complications six months after placement is notable. Several methods are available for IGB placement and new techniques are being developed to reduce discomfort during and after the procedure. Thus, the use of an IGB as an effective method to avoid bariatric surgery is proposed. However, the precise protocol to balance complications and discomfort while maximizing weight loss is still to be established.
Our secondary objectives will be:
- Describe the weight loss, changes in the BMI and excess weight loss between the implantation of the first IGB until its removal;
- Describe changes in the components of the metabolic syndrome;
- Describe changes in blood pressure;
- Estimate the rate of early explant;
- Describe the conditions of surgery;
- Describe operative complications;
- To describe safety in the perioperative period, in the immediate postoperative period and in the late postoperative period
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
Sao Paolo
-
Santo Andre, Sao Paolo, Brazil
- School of Medice of ABC
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Class I obesity (30-34.9 kg/m2), Class II obesity (35-39.5 kg/m2) or overweight (25-29.9 kg/m2).
Exclusion Criteria:
- Morbid obesity (BMI>40kg/m2), operative contraindications.
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Obese individuals
Obese patients submitted to treatment using two consecutively air-filled IGB (Heliosphere® 600 cc and Heliosphere 720 cc) without any interval between the removal of the first and the placement of the second.
|
Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Weight loss
Time Frame: 12 months
|
Subtraction of the Final body mass index (BMI ) after 12 months of IGB placement minus the initial BMI
|
12 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of early explant
Time Frame: 12 months
|
Rate of patients in which the balloon was extracted early
|
12 months
|
|
Operative complications
Time Frame: Through endoscopy completion, an average of 2 hours
|
Rate of complications during the placement of the balloon
|
Through endoscopy completion, an average of 2 hours
|
|
Change in blood pressure
Time Frame: 12 months
|
Arterial blood pressure will be measured before and after IGB using an digital sphygmomanometer
|
12 months
|
|
Changes Glycated hemoglobin (HbA1c)
Time Frame: 12 months
|
Blood measurements of Glycated hemoglobin (HbAq1c) will be reported in International Federation of Clinical Chemistry and Laboratory Medicine Units
|
12 months
|
|
Physical activity
Time Frame: 12 months
|
Physical activity will be self-reported on a weekly basis
|
12 months
|
|
Caloric intake
Time Frame: 12 months
|
Caloric intake will be self-reported on a weekly basis
|
12 months
|
|
Excess weight loss
Time Frame: 12 months
|
Measure that relates the preoperative weight, the postoperative weight and ideal weight
|
12 months
|
|
Posoperative complications
Time Frame: Through posToperative period completion, an average of 72 hours after the termination of surgery
|
Rate of postoperative complications
|
Through posToperative period completion, an average of 72 hours after the termination of surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: Eduardo Grecco, MD, School of Medicine of ABC, Santo Andre/SP Brazil
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- kaiserairballoonobesity
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Obesity
-
NCT06671119RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | Obesity and Obesity-related Medical Conditions
-
NCT05938335Not yet recruiting
-
NCT02645422Enrolling by invitation
-
NCT04780828CompletedObesity, Morbid | Obesity, Adolescent | Obesity, Abdominal | Weight, Body | Obesity, Visceral
-
NCT03203161Not yet recruitingMorbid Obesity | Adolescent Obesity | Bariatric Surgery
-
NCT03843424CompletedOvernutrition | Nutrition Disorders | Overweight | Body Weight | Pediatric Obesity | Body Weight Changes | Childhood Obesity | Weight Gain | Adolescent Obesity | Obesity, Childhood
-
NCT06734312RecruitingObesity Prevention | Obesity Recidivism | Obesity and Overweight | GLP-1 | Obesity and Obesity-related Medical Conditions | Ablation Techniques
-
NCT03219658Completed
-
NCT03899311Completed
-
NCT04698135CompletedMorbid Obesity | Metabolically Healthy Obesity
Clinical Trials on Air-filled Intragastric balloon
-
NCT02129296UnknownWeight Loss | Morbid Obesity | Tolerance
-
NCT00204763TerminatedAchalasia | Fecal Incontinence | Scleroderma | Esophageal Spasm | Nutcracker Esophagus
-
NCT07062094Recruiting
-
NCT06673550Recruiting
-
NCT00355979Unknown
-
NCT03530410WithdrawnObesity | Obesity, Morbid
-
NCT02802007Unknown
-
NCT02003872TerminatedHypertension | Obesity | Diabetes